PARP7 Suppresses Radiation-induced Necroptosis and Abscopal Immunity
Authors:
- Gaorav GuptaGGGaorav Gupta
- Anna GoddardAGAnna Goddard
- Sierra McDonaldSMSierra McDonald
- Lynn LernerLLLynn Lerner
- Maxwell FinkelsteinMFMaxwell Finkelstein
- Qinhong WangQWQinhong Wang
- Min-Guk ChoMCMin-Guk Cho
- Simon EllingtonSESimon Ellington
- Matthew SutcliffeMSMatthew Sutcliffe
- Kevin Raynard MottKMKevin Raynard Mott
- William GreenWGWilliam Green
Preprint
- 7 November 2025
- preprint
- Published by Springer Nature in Research Square
Abstract
The abscopal effect, in which local radiotherapy (RT) drives regression of distant tumors, remains unpredictable and mechanistically elusive. Using a panel of p53-null murine breast cancer models, we identified tumor-intrinsic determinants of abscopal competence to RT and immune checkpoint inhibitors (ICI). Abscopal-competent tumors exhibited heightened type I interferon stimulated gene (ISG) expression, induction of the necroptosis mediator ZBP1, and recruitment of antigen-presenting cells (APCs) and effector T cells in distant tumors. Transcriptomic analyses revealed PARP7 as a tumor-intrinsic suppressor of RT-induced ISGs and necroptosis. Pharmacologic PARP7 inhibition amplified RT-driven ISGs and ZBP1-dependent necroptosis. In vivo , PARP7 blockade combined with RT + ICI conferred abscopal competency to resistant tumors, improving distant tumor control, systemic immune activation, and survival. Notably, ZBP1 loss abrogated these effects, preventing APC recruitment and T cell priming. These findings establish PARP7 and necroptosis as opposing regulators of abscopal responses and nominate PARP7 inhibition as a strategy to overcome RT + ICI resistance.Keywords
All Related Versions
This publication has 68 references indexed in Scilit:
- Enhancer-driven gene regulatory networks reveal transcription factors governing T cell adaptation and differentiation in the tumor microenvironmentImmunity, 2025
- Single-cell and spatial profiling identify three response trajectories to pembrolizumab and radiation therapy in triple negative breast cancerCancer Cell, 2024
- The Next Chapter in Immunotherapy and Radiation Combination Therapy: Cancer-Specific PerspectivesInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2024
- High-dose paclitaxel and its combination with CSF1R inhibitor in polymeric micelles for chemoimmunotherapy of triple negative breast cancerNano Today, 2023
- Necroptosis is associated with Rab27‐independent expulsion of extracellular vesicles containing RIPK3 and MLKLJournal of Extracellular Vesicles, 2022
- TRIM34 modulates influenza virus-activated programmed cell death by targeting Z-DNA-binding protein 1 for K63-linked polyubiquitinationJournal of Biological Chemistry, 2022
- PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunityCancer Cell, 2021
- B Cells and T Follicular Helper Cells Mediate Response to Checkpoint Inhibitors in High Mutation Burden Mouse Models of Breast CancerCell, 2019
- An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome AnalyticsCell, 2018
- STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic TumorsImmunity, 2014